| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We successfully generated multiple iPS cell lines from abnormal clones of patients with myelodysplastic syndromes or secondary AML (MDS/sAML) evolved from MDS. Hematopoietic progenitor cells (HPCs) differentiated from MDS-derived MDS-iPS cell lines showed decreased colony formation, whereas HPCs differentiated from sAML-derived MDS-iPS cell lines showed increased colony formation, compared with isogenic normal iPS cell lines, and induced lethal AML in transplanted immunodeficient mice. Next, we performed whole-exome analysis to find that some of the somatic mutations detected in bulk cells of MDS/sAML patients are shared in MDS-iPS cell lines but not in isogenic normal iPS cell lines. Furthermore, we performed coprehensive gene expression analysis in hematopoietic progenitor cells differentiated from MDS-iPS cell lines and isogenic normal iPS cell lines, identifying disease-specific expression change.
|
